The Management of Obesity in 2023: An Update

Stephen A Glazer

doi:10.58931/cpct.2023.118

Auteurs-es

Stephen A. Glazer, MD, FRCPC, FCCP, FAASM

Résumé

En 2015, l’Association médicale canadienne (AMC) et d’autres organisations mondiales de santé (l’Organisation mondiale de la Santé [OMS], la World Obesity Federation et l’American Medical Association [AMA]) ont déclaré que l’obésité est une affection chronique, récidivante et rémittente, provoquée par le dépôt de tissus adipeux dans les systèmes d’organes du corps, ce qui entraîne un dysfonctionnement et des effets néfastes sur la santé. De la même manière que d’autres maladies chroniques comme le diabète, l’hypertension ou la coronaropathie, l’obésité doit être prise en charge sur le plan médical.

Biographie de l'auteur-e

Stephen A. Glazer, MD, FRCPC, FCCP, FAASM

Le Dr Stephen Glazer est titulaire d’une certification en médecine interne et en médecine des soins intensifs de l’Université de Toronto (Ontario). Il est également certifié par l’Ordre des médecins et chirurgiens de l’Ontario en tant que spécialiste de la médecine du sommeil. Il est fortement intéressé par l’évaluation des risques périopératoires.

Le Dr Glazer est un chef de file du domaine de la médecine bariatrique au niveau provincial et national. En 2010, il est devenu directeur médical du programme de chirurgie et de médecine bariatrique du Humber River Hospital, un centre d’excellence dédié à la prise en charge de l’obésité en Ontario. Il est un membre actif du conseil d’administration du Réseau bariatrique de l’Ontario, siégeant à de nombreux sous-comités, notamment en tant que vice-président du groupe de travail sur le programme médical du Réseau bariatrique de l’Ontario. Il contribue à l’établissement des normes de soins pour les patients de l’Ontario qui ont recours à des approches chirurgicales et médicales pour perdre du poids. En 2012, il a été l’un des premiers médecins canadiens à réussir l’examen de certification de l’American Board of Obesity Medicine (ABOM) et il est ambassadeur de l’ABOM.

En 2019, le Dr Glazer est devenu président de la Canadian Association of Bariatric Physicians and Surgeons (CABPS), une organisation nationale représentant les spécialistes canadiens qui s’intéressent au traitement de l’obésité afin de maintenir et d’améliorer les normes de soins bariatriques au Canada, en soutenant à la fois les programmes de formation initiale et continue, le développement des connaissances, la recherche et l’élaboration de politiques et l’émergence de nouvelles idées dans les domaines des soins cliniques, de la formation et de la recherche en médecine et en chirurgie bariatriques.

Le Dr Glazer participe à de nombreux projets de recherche clinique et à des publications. Il est l’auteur du chapitre sur la prise en charge préopératoire pour la chirurgie bariatrique figurant dans les lignes directrices canadiennes de pratique clinique de l’obésité publiées en 2020. Ce qu’il apprécie le plus, c’est d’enseigner et d’avoir des interactions avec d’autres professionnels de la santé lors des conférences qu’il donne ou lors d’autres activités pédagogiques. Il manifeste un enthousiasme et une passion pour le domaine de la médecine de l’obésité et des soins aux patients souffrant d’obésité et il espère les communiquer aux autres.

Références

World Health Organization. Obesity and overweight. World Health Organization. 2018 [updated 2021 Jun 9]. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.

Statistics Canada. Table 13-10-0096-20. Body mass index, overweight or obese, self-reported, adult, age groups (18 years and older). Statistics Canada. 2022 Aug 26. doi:10.25318/1310009601-eng

Twells LK, Gregory DM, Reddigan J, Midodzi WK. Current and predicted prevalence of obesity in Canada: A trend analysis. CMAJ Open. 2014;2(1): E18-E26. doi:10.9778/cmajo.20130016

Elflein J. Percentage of Canadian adults that are overweight or obese based on BMI from 2015 to 2021. Statists. 2022 Sep 9. https://www.statista.com/statistics/748339/share-of-canadians-overweight-or-obese-based-on-bmi.

Public Health Agency of Canada. Tackling obesity in Canada: Childhood obesity and excess weight rates in Canada. Public Health Agency of Canada. 2017 Jan 22 [updated 2018 Feb 18]. https://www.canada.ca/en/public-health/services/publications/healthy-living/obesity-excess-weight-rates-canadian-children.html.

Public Health Agency of Canada. Obesity in Canada – Snapshot: Figure 2. Public Health Agency of Canada. 2009 Jun 26. https://www.canada.ca/en/public-health/services/reports-publications/obesity-canada-snapshot.html.

Public Health Agency of Canada. Obesity in Canada – Snapshot: Figure 3. Public Health Agency of Canada. 2009 Jun 26. https://www.canada.ca/en/public-health/services/reports-publications/obesity-canada-snapshot.html.

Statistics Canada. Obesity in Canadian Adults, 2016 and 2017. Statistics Canada. 2018 Oct 24 [updated 2019 Apr 26]. https://www150.statcan.gc.ca/n1/pub/11-627-m/11-627-m2018033-eng.htm.

Rao DP, Krupa E, Do MT, Roberts KC, Jayaraman GC. Childhood overweight and obesity trends in Canada. Heal Promot Chronic Dis Prev Can. 2016;36(9):194-8. doi:10.24095/hpcdp.36.9.03

Anis AH, Zhang W, Bansback N, Guh DP, Amarsi Z, Birmingham CL. Obesity and overweight in Canada: An updated cost-of-illness study. Obes Rev. 2010;11(1):31-40. doi:10.1111/j.1467-789X.2009.00579.x

Public Health Agency of Canada. Obesity in Canada: Health and economic implications. Public Health Agency of Canada. 2011 Jun 10. https://www.canada.ca/en/public-health/services/health-promotion/healthy-living/obesity-canada/health-economic-implications.html.

World Obesity Atlas 2022. World Obesity Federation. 2022 Mar 4. https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2022.

Sharma AM, Padwal R. Obesity is a sign – over-eating is a symptom: an aetiological framework for the assessment and management of obesity. Obes Rev. 2010;11(5):362-70. doi: 10.1111/j.1467-789X.2009.00689.x

Chesi A, Grant SF. The genetics of pediatric obesity. Trends Endocrinol Metab. 2015;26(12):711-21. doi:10.1016/j.tem.2015.08.008

Mathew B, Francis L, Kayalar A, Cone J. Obesity: effects on cardiovascular disease and its diagnosis. J Am Board Fam Med. 2008;21(6):562-8. doi:10.3122/jabfm.2008.06.080080

Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003 Jan 1;289(1):76-9. doi:10.1001/jama.289.1.76

Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010 Mar;67(3):220-9. doi:10.1001/archgenpsychiatry.2010.2

Parkin DM, Boyd L, Walker LC. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer. 2011 Dec 6;105(Suppl 2):S77-81. doi:10.1038/bjc.2011.489

Catenacci VA, Hill JO, Wyatt HR. The obesity epidemic. Clin Chest Med. 2009 Sep;30(3):415-44, vii. doi:10.1016/j.ccm.2009.05.001

Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, Cunningham G. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011 Jul;34(7):1669-75. doi:10.2337/dc10-2339

Lauby-Secretan B, Vilahur N, Bianchini F, Guha N, Straif K. The IARC perspective on colorectal cancer screening. N Engl J Med. 2018 May 3;378(18):1734-40. doi:10.1056/NEJMsr1714643

Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15(6):556-65. doi:10.1634/theoncologist.2009-0285

Prospective Studies Collaboration; Whitlock G, Lewington S, et al. Body mass index and cause-specific mortality in 900 000 adults: Collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083-96. doi:10.1016/S0140-6736(09)60318-4

Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. J Am Med Assoc. 2003;289(2):187-93. doi:10.1001/jama.289.2.187

Cefalu WT, Bray GA, Home PD, Garvey WT, Klein S, Pi-Sunyer FX, et al. Advances in the science, treatment, and prevention of the disease of obesity: reflections from a diabetes care editors’ expert forum. Diabetes Care. 2015;38(8):1567-82.

Brown J, Clarke C, Johnson Stoklossa C, Sievenpiper J. Canadian adult obesity clinical practice guidelines: medical nutrition therapy in obesity management. Obesity Canada. 2020 Aug 4 [updated 2022 Oct 21]. https://obesitycanada.ca/guidelines/nutrition.

Boulé NG, Prud’homme D. Canadian adult obesity clinical practice guidelines: physical activity in obesity management. Obesity Canada. 2020 Aug 4 [updated 2021 Mar 29]. https://obesitycanada.ca/guidelines/physicalactivity.

Vallis TM, Macklin D, Russell-Mayhew S. Canadian adult obesity clinical practice guidelines: effective psychological and behavioural interventions in obesity management. Obesity Canada. 2020 Aug 4. https://obesitycanada.ca/guidelines/behavioural.

Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007 Dec 8;335(7631):1194-9. doi:10.1136/bmj.39385.413113.25

Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015 Jul 2;373(1):11-22. doi:10.1056/NEJMoa1411892

le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomized, double-blind trial. Lancet. 8 Apr 2017;389(10077):1399-409. doi:10.1016/S0140-6736(17)30069-7

Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015 Aug 18;314(7):687-99. doi:10.1001/jama.2015.9676

Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2009 Jan;17(1):30-9. doi:10.1038/oby.2008.461

Booth K, Clements JN. Role of bupropion plus naltrexone for the management of obesity. J Pharm Technol. 2016 Jun;32(3):125-32. doi:10.1177/8755122515624220

Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021 Mar;23(3):754-62. doi:10.1111/dom.14280

Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi:10.1056/NEJMoa2032183

Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-25. doi:10.1001/jama.2021.3224

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022 Jul 21;387(3):205-16. doi:10.1056/NEJMoa2206038

Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2022 Dec;18(12):1345-56. doi:10.1016/j.soard.2022.08.013

Gondal AB, Hsu CH, Zeeshan M, Hamidi M, Joseph B, Ghaderi I. A frailty index and the impact of frailty on postoperative outcomes in older patients after bariatric surgery. Surg Obes Relat Dis. 2019 Sep;15(9):1582-8. doi:10.1016/j.soard.2019.06.028

Marceau P, Biron S, Marceau S, et al. Long-term metabolic outcomes 5 to 20 years after biliopancreatic diversion. Obes Surg. 2015 Sep;25(9):1584-93. doi:10.1007/s11695-015-1599-5.

Kapeluto JE, Tchernof A, Masckauchan D, Biron S, Marceau S, Hould FS, Lebel S, Lescelleur O, Julien F, Biertho L. Ten-year remission rates in insulin treated type 2 diabetes after biliopancreatic diversion with duodenal switch. Surg Obes Relat Dis. 2020 Nov;16(11):1701-12. doi:10.1016/j.soard.2020.06.052

Enochs P, Bull J, Surve A, Cottam D, Bovard S, Bruce J, et al. Comparative analysis of the single-anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S) to established bariatric procedures: an assessment of 2-year postoperative data illustrating weight loss, type 2 diabetes, and nutritional status in a single US center. Surg Obes Relat Dis. 2020 Jan;16(1):24-33. doi:10.1016/j.soard.2019.10.008

Nguyen NT, Kim E, Vu S, Phelan M. Ten-year outcomes of a prospective randomized trial of laparoscopic gastric bypass versus laparoscopic gastric banding. Ann Surg. 2018;268(1):106-13. doi:10.1097/SLA.0000000000002348

Adams TD, Gress RE, Sherman SC, Halverson RC, Simper SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007 Aug 23;357(8):753-61. doi: 10.1056/NEJMoa066603

Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-center, randomized controlled trial. Lancet. 2015;386(9997):964-973. doi:10.1016/S0140-6736(15)00075-6

Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes – 5-year outcomes. N Engl J Med. 2017;376(7):641-51. doi:10.1056/NEJMoa1600869

Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007 Aug 23;357(8):741-52. doi: 10.1056/NEJMoa066254

Pedersen SD, Manjoo P, Wharton S. Canadian adult obesity clinical practice guidelines: pharmacotherapy for obesity management. Obesity Canada. 2022 Oct 21. https://obesitycanada.ca/guidelines/pharmacotherapy.

La prise en charge de l'obésité en 2023 : nouveautés

Auteurs-es

Résumé

Biographie de l'auteur-e

Stephen A. Glazer, MD, FRCPC, FCCP, FAASM

Références

Téléchargements

Publié

Comment citer

Numéro

Rubrique

Licence

Comment citer

Survol

Libre accès

Licence